Yeah, docs getting money from pharma companies is so much

New Post Public Reply Private Reply Replies (1) Message Board
Respert24 SporadicE #142787
680
Yeah, docs getting money from pharma companies is so much more limited these last 10+ years than it was before. There is a database to track what each doctor receives from pharma so you can look it up as a patient. There are all sorts of rules in place for a dinner program, which is/was a very common practice at the territory level and one of the main ways doctors got paid. In 2004 you could take a doctor out to dinner for no reason. It wasn't but a year or two later before it had to be a speaking engagement with attendees. Had to be run through the organization and the limits and rules were tight. It honestly started to feel like a waste of time.

That being said, the "gurus" in each region were definitely being asked to speak about drugs and taking a payday to do so. But they were also held to an approved speaker deck of presentation materials and outside of offering their unique thoughts during Q&A it was always frustrating that these "thought leaders" were taking a nice paycheck home for delivering the same information the reps were delivering in the field. They just did it over either steak, salmon, or chicken with house wine or beer included.

There's a LOT of nuance that goes into what a doctor prescribes, including if they're being paid. Just because they're paid doesn't mean it's not still the best drug. It doesn't mean that they could even prescribe another, as insurance companies are like fucking mob bosses about what they allow doctors to do. Or put another way, what they will cover.

I remember a primary care doctor telling me he was no longer allowed to perform the two common (and complimentary) tests for heart health in his office on the same day anymore. They'd literally still cover/pay for both, but they wanted to make the patient come back for a second visit. No way around it for the doctors.

Bottom line, while pharma takes the brunt of the furor it's insurance companies that deserve a significant chunk of that frustration.

But back to the prescribers. They will often take the path of least resistance. If it's covered on their major plan they start there for every patient because they're less likely to find out the patient's insurance won't cover it or that the patient shows up to the pharmacy and finds out the cost of their script is $450. They blame the doc when it's really more of an insurance issue.

Insurance companies get rebates from the pharma companies by moving certain quantities of their drugs, so it's in their best interest to keep prices down by forcing doctors to prescribe what makes them the most money.

I've probably told it here before, but the head of trauma urology at a major hospital system once told a crowd of doctors that his hospital had multiple days of meetings to try to figure out if they should continue the older TUNA procedure that has more side effects but gets you more money out of the insurance carrier, or perform the newer and safer TURP that paid a quarter of the reimbursement. They finally settled on doing the TURP since it was best for the patient, but it wasn't an easy decision when for profit assholes are staring at what could be a cash cow instead of settling for an ATM with a withdrawal limit.

It's a bell curve. Most are good, solid doctors. A small amount are great and a small amount are terrible. But they also are stuck in a system that is dysfunctional at just about every level. I found that most tried quite hard to do what was right even though it was a more difficult path to take.

And to the folks talking about having a billionaire try an end around toward approval, it's both never going to happen and a terrible idea.

You've all probably heard the phrase "you never call another person's baby a Craig". Despite our thoughts on the organization, they are in full control and would be happy to delay a company who Amarex's their way through the process with concerns over spelling errors or missing punctuation.

It would be company seppuku to signal to the fda that we don't plan on playing their games. It's a bad system but it's too big and too entrenched as an entity to do anything about it while we're all still kicking.

Besides, we're already not owned by big pharma and already working on doing trials. Sure, it would be great if we knew where our money was coming from but we'll get there. Why try to skirt the system when we can latch onto it like a puppy and hump our way to approval the old fashioned way. By earning it.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Phoenix Initiative Delivers Meals, Health Aid Downtown

Updated Category News Views 5

Phoenix's Fight Against Homelessness Gets Personal When you hit the streets of downtown Phoenix on a scorching Saturday morning, you're not just encountering sweltering heat; you're witnessing compassion in motion. An unexpected coalition has emerged, unraveling the web of homelessness in the heart of Arizona. Forget the stock tips, this one’s about community fortitude....

Continue Reading
Union Savings Bank Leverages AI for Strategic Growth

Updated Category News Views 4

USB's Data-Driven Approach Transforms Banking Remember the days of handing out toasters to keep customers? Union Savings Bank (USB) sure doesn't seem to, as it embraces tech-savvy methods to keep its clientele content. Instead, the $3.3 billion community bank based in Danbury, Connecticut, has deployed NGDATA's AI Hub, transforming its approach to reducing customer churn...

Continue Reading
Innventure Faces Class Action Over Alleged Deception

Updated Category News Views 0

Unpacking the Innventure Debacle Innventure, Inc. (NASDAQ:INV) seems to have landed itself in hot water, and not the relaxing kind. The revelation that its grand AI data center project in Ontario might never have existed has stirred up quite a storm among shareholders. This isn't just some run-of-the-mill oversight. We're talking about allegations of concocted stories...

Continue Reading
Salute's T5 Acquisition: A Big Leap in AI/Data Centers

Updated Category News Views 103

Salute's Bold Strategic Acquisition The only constant in the ever-evolving data center industry is change, and Salute has made a significant leap by acquiring T5 Operations. This move fortifies Salute's standing as a leading global service provider for AI, HPC, and cloud infrastructure. By integrating T5's first-rate expertise with their own, Salute isn't just playing the...

Continue Reading
Robo.ai Surpasses $180 Million in Q2 Revenue Surge

Updated Category News Views 0

Robo.ai's Financial Rocket Lift-off: Q2 Highlights Who would've thought a single acquisition could propel a company's revenue north of $180 million in just three months? Well, Robo.ai, with its recent grab of Quantum Core Capital (QC Capital), shattered that ceiling, showcasing what a savvy acquisition and a dash of tech wizardry can achieve. Strong Quarter, Stronger...

Continue Reading
Broadridge Expands Tokenization with G7 Securities

Updated Category News Views 4

Broadridge Takes a Big Step with G7 Integration Broadridge Financial Solutions is pulling no punches with its latest move—integrating G7 securities into its Distributed Ledger Repo (DLR) network. This isn't your average fintech maneuver; it's a heavyweight shift intended to redefine the way global financing and collateral markets work. Tokenized Repo: More Than Just a...

Continue Reading
Senior Care's Future: AI and Expert Insights Collide

Updated Category News Views 1

The Inflection Point in Senior Care We’re standing at a crossroads, folks. The senior care industry is feeling the pressure from all sides: a growing aging population, relentless staffing shortages, and increasing demands for transparency. So, what do you do when you're trying to keep a sinking ship afloat? Well, Sensi.AI reckons it’s time to call in the big guns. A...

Continue Reading
Celebree School Champions Screen-Free Imagination Era

Updated Category News Views 3

Nostalgia often carries us back to simpler times, whether it's building blanket forts or putting on living room plays. Today, these memories are stirring up a movement, and Celebree School is at the heart of the whirlwind. They're rolling out a campaign aptly titled "Boredom Is Where Imagination Begins," aimed at reintroducing children to creativity beyond screens and...

Continue Reading
Acer's New Monitors: ePaper, Triple Displays & More

Updated Category News Views 4

Next-Gen Screens: Breakthrough or Bust? So, Acer’s stepping up its game, unveiling an armory of gadgets designed to cement their spot in the tech arena. On the menu today? ePaper displays and enhanced connectivity gizmos that could either tip the scales or sink like a stone. Keep your eyes peeled, though—these updates aren't just another throwaway press release....

Continue Reading
Olive Tree People Brings Waterless Beauty to the U.S.

Updated Category News Views 2

Olive Trees and Beauty: A New California Installment When you hear Olive Tree People, you might not instantly think of beauty products. Still, that's precisely what's making waves over on Abbot Kinney Boulevard in Venice, California. They've launched their first U.S. flagship, and it's not just about selling products—it's a downright spectacle of innovation. With 45,000...

Continue Reading

Top 5 Most Recently Viewed Articles

Bank Stocks Surge 7% This Month, Outshining Competitors

Updated Category News Views 204

Bank Stocks on the Rise Recently, bank stocks have experienced a substantial increase of 7% since the beginning of the month, demonstrating strong performance amidst a market landscape where they have outpaced major indices such as the Nasdaq and the S&P 500. It's fascinating to see how bank stocks, often viewed as dull, have become some of the hottest assets in the...

Continue Reading
Estee Lauder Adjusts Growth Strategies Amid Price Target Cuts

Updated Category News Views 94

Recent Adjustments to Estee Lauder's Market Outlook Recently, significant changes have been made regarding Estee Lauder's financial expectations. An analyst from TD Cowen has revised the price target for Estee Lauder (NYSE: EL) shares down to $70, previously set at $95, while maintaining a Hold rating on the stock. This adjustment signals a more conservative approach to...

Continue Reading
Ondas Holdings Enhances AI Drone Capabilities for Defense

Updated Category News Views 283

Ondas Holdings Strengthens Position in the Defense Sector Ondas Holdings is on a positive trajectory as it looks to secure more orders over the coming year, which would significantly bolster the development of its innovative drone systems and supporting infrastructure. The focus is on enhancing the practical uses of its AI-integrated drone platform, thereby increasing its...

Continue Reading
Fortuna Mining Corp. Plans Second Quarter Financial Report Release

Updated Category News Views 132

Fortuna Mining Corp. Announces Q2 2025 Financial Results Fortuna Mining Corp. is preparing to release its financial statements for the second quarter of 2025 on August 6, a pivotal event for investors and stakeholders alike. The announcement will be made after the market closes, providing comprehensive insights into the company's recent performance. Details of the...

Continue Reading
Mowi's Strategic Growth Plans for Volume and Cost Efficiency

Updated Category News Views 148

Mowi's Ambitious Growth Strategy Unveiled When it comes to dominating the seafood scene, Mowi isn’t just dipping its toes in—it's cannonballing into the deep end. At a recent capital markets day in Trøndelag, the world’s largest producer of Atlantic salmon laid out some jaw-dropping ambitions. CEO Ivan Vindheim announced plans to amp up production from an already...

Continue Reading